Immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 are promising new immunotherapy targets for the treatment of cancer and autoimmunity. Immune checkpoint reporter-based bioassays provide a simple, consistent, and reliable cell-based assay to measure Ab function throughout the drug development pipeline.
The brief chalk talk below describes the assay principals of the reporter-based bioassay that monitors the functional blockade of PD-1/PD-L1 interactions.
Latest posts by Kelly Grooms (see all)
- RT-qPCR and qPCR Assays—Detecting Viruses and Beyond - April 20, 2020
- Optimizing PCR: One Scientist’s Not So Fond Memories - July 31, 2019
- Selecting the Right Colony: The Answer is There in Blue and White - June 21, 2019